Business
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract has been selected for publication at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29 – June 2, 2026 in Chicago, Illinois. The abstract details positive clinical data from studies of predictive biomarkers in pat
About this update from Genprex, Inc.
[{"type":"text","content":"AUSTIN, Texas, April 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract has been selected for publication at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29 – June 2, 2026 in Chicago, Illinois. The abstract details positive clinical data from studies of predictive biomarkers in patients receiving its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of lung cancer.","length":694,"tagName":"p"},{"type":"image","alt":"Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)","displaySize":"","headline":null,"caption":"Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/f50a341694cf7fe551faa42c59d58c55"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_iifL5YQS5ZkyGbI2UcMmQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1Mw--/https://media.zenfs.com/en/prnewswire.com/f50a341694cf7fe551faa42c59d58c55","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/1798169/Genprex_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are pleased to be selected for publication at the 2026 ASCO Annual Meeting, one of the leading medical meetings for physicians and oncology professionals caring for people with cancer," said Ryan Confer, President and Chief Executive Officer at Genprex. "We are also excited to share our latest research on predictive biomarkers that may help enrich our lung cancer clinical trials. We believe this research may help predict patient response to REQORSA treatment, which could lead to improved patient outcomes."","length":535,"tagName":"p"},{"type":"text","content":"The featured Genprex-supported abstract at ASCO 2026:","length":53,"tagNa...